Baxter (BAX) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Medical Products And TherapiesHealthcare Systems and TechnologiesPharmaceuticals
0500M1B2B2B2B3B4B4BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

UNITED STATESWestern Europe, Canada, Japan, Australia and New ZealandEMEANon-US
0500M1B2B2B2B3B4B4BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0625M1B2B2B3B4B4B5BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-600M-450M-300M-150M0150M300M450M600MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

EPSEPS Diluted
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-20-16-13-9-6-2259Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
03757501K2K2K2K3K3KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
0124568910Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
03875112150188225262300Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-200-169-138-106-75-44-121950Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0510152025303540Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
050M100M150M200M250M300M350M400MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
012345678Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics